Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.18/7937 |
Resumo: | Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 42]; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P < .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa [n = 19], 26% [95% CI, 10 to 47], clonal ALKm [n = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration [n = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. Conclusion: Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations. |
id |
RCAP_83474814e43230d34006bb4bed7a2a44 |
---|---|
oai_identifier_str |
oai:repositorio.insa.pt:10400.18/7937 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)NeuroblastomaALKPrognostic ImpactEuropean Neuroblastoma Study GroupSIOPENDoenças GenéticasPurpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 42]; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P < .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa [n = 19], 26% [95% CI, 10 to 47], clonal ALKm [n = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration [n = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. Conclusion: Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations.Key Objective: High risk neuroblastoma (HR-NB) is one of the most difficult childhood cancers to cure. This study examined whether the presence of an ALK alteration (amplification or mutation) was associated with a poor prognosis in a large patient series treated on the prospective European high-risk neuroblastoma trial (HR-NBL1). Knowledge Generated: We found that ALK amplification or clonal mutation was associated with inferior prognosis in patients with HR-NB and both are independent prognostic variables on multivariate analysis. To our knowledge, this is the first study to report the highly prognostic significance of ALK amplification in HR-NB. Relevance: As ALK can be targeted therapeutically, this study convincingly argues for the introduction of ALK inhibitors for upfront management of patients with HR-NB with ALK aberrations. Importantly, the prognostic significance of ALK alterations included a subgroup of trial patients treated with the current standard of care for HR-NB including anti-GD2 immunotherapy.American Society of Clinical OncologyRepositório Científico do Instituto Nacional de SaúdeBellini, AngelaPötschger, UlrikeBernard, VirginieLapouble, EveBaulande, SylvainAmbros, Peter F.Auger, NathalieBeiske, KlausBernkopf, MarieBetts, David R.Bhalshankar, JayduttBown, Nickde Preter, KatleenClément, NathalieCombaret, ValérieFont de Mora, JaimeGeorge, Sally L.Jiménez, IreneJeison, MartaMarques, BarbaraMartinsson, TommyMazzocco, KatiaMorini, MartinaMühlethaler-Mottet, AnnickNoguera, RosaPierron, GaelleRossing, MariaTaschner-Mandl, SabineVan Roy, NadineVicha, AlesChesler, LouisBalwierz, WalentynaCastel, VictoriaElliott, MartinKogner, PerLaureys, GenevièveLuksch, RobertoMalis, JosefPopovic-Beck, MajaAsh, ShifraDelattre, OlivierValteau-Couanet, DominiqueTweddle, Deborah A.Ladenstein, RuthSchleiermacher, Gudrun2022-02-04T17:35:31Z2021-06-112021-06-11T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/7937engJ Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11.0732-183X10.1200/JCO.21.00086info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:42:21Zoai:repositorio.insa.pt:10400.18/7937Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:42:39.355165Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
title |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
spellingShingle |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) Bellini, Angela Neuroblastoma ALK Prognostic Impact European Neuroblastoma Study Group SIOPEN Doenças Genéticas |
title_short |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
title_full |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
title_fullStr |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
title_full_unstemmed |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
title_sort |
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) |
author |
Bellini, Angela |
author_facet |
Bellini, Angela Pötschger, Ulrike Bernard, Virginie Lapouble, Eve Baulande, Sylvain Ambros, Peter F. Auger, Nathalie Beiske, Klaus Bernkopf, Marie Betts, David R. Bhalshankar, Jaydutt Bown, Nick de Preter, Katleen Clément, Nathalie Combaret, Valérie Font de Mora, Jaime George, Sally L. Jiménez, Irene Jeison, Marta Marques, Barbara Martinsson, Tommy Mazzocco, Katia Morini, Martina Mühlethaler-Mottet, Annick Noguera, Rosa Pierron, Gaelle Rossing, Maria Taschner-Mandl, Sabine Van Roy, Nadine Vicha, Ales Chesler, Louis Balwierz, Walentyna Castel, Victoria Elliott, Martin Kogner, Per Laureys, Geneviève Luksch, Roberto Malis, Josef Popovic-Beck, Maja Ash, Shifra Delattre, Olivier Valteau-Couanet, Dominique Tweddle, Deborah A. Ladenstein, Ruth Schleiermacher, Gudrun |
author_role |
author |
author2 |
Pötschger, Ulrike Bernard, Virginie Lapouble, Eve Baulande, Sylvain Ambros, Peter F. Auger, Nathalie Beiske, Klaus Bernkopf, Marie Betts, David R. Bhalshankar, Jaydutt Bown, Nick de Preter, Katleen Clément, Nathalie Combaret, Valérie Font de Mora, Jaime George, Sally L. Jiménez, Irene Jeison, Marta Marques, Barbara Martinsson, Tommy Mazzocco, Katia Morini, Martina Mühlethaler-Mottet, Annick Noguera, Rosa Pierron, Gaelle Rossing, Maria Taschner-Mandl, Sabine Van Roy, Nadine Vicha, Ales Chesler, Louis Balwierz, Walentyna Castel, Victoria Elliott, Martin Kogner, Per Laureys, Geneviève Luksch, Roberto Malis, Josef Popovic-Beck, Maja Ash, Shifra Delattre, Olivier Valteau-Couanet, Dominique Tweddle, Deborah A. Ladenstein, Ruth Schleiermacher, Gudrun |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Nacional de Saúde |
dc.contributor.author.fl_str_mv |
Bellini, Angela Pötschger, Ulrike Bernard, Virginie Lapouble, Eve Baulande, Sylvain Ambros, Peter F. Auger, Nathalie Beiske, Klaus Bernkopf, Marie Betts, David R. Bhalshankar, Jaydutt Bown, Nick de Preter, Katleen Clément, Nathalie Combaret, Valérie Font de Mora, Jaime George, Sally L. Jiménez, Irene Jeison, Marta Marques, Barbara Martinsson, Tommy Mazzocco, Katia Morini, Martina Mühlethaler-Mottet, Annick Noguera, Rosa Pierron, Gaelle Rossing, Maria Taschner-Mandl, Sabine Van Roy, Nadine Vicha, Ales Chesler, Louis Balwierz, Walentyna Castel, Victoria Elliott, Martin Kogner, Per Laureys, Geneviève Luksch, Roberto Malis, Josef Popovic-Beck, Maja Ash, Shifra Delattre, Olivier Valteau-Couanet, Dominique Tweddle, Deborah A. Ladenstein, Ruth Schleiermacher, Gudrun |
dc.subject.por.fl_str_mv |
Neuroblastoma ALK Prognostic Impact European Neuroblastoma Study Group SIOPEN Doenças Genéticas |
topic |
Neuroblastoma ALK Prognostic Impact European Neuroblastoma Study Group SIOPEN Doenças Genéticas |
description |
Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with a significantly poorer overall survival (OS) (5-year OS: ALKa [n = 41] 28% [95% CI, 15 to 42]; no-ALKa [n = 860] 51% [95% CI, 47 to 54], [P < .001]), particularly in cases with metastatic disease. ALK mutations (ALKm) were detected at a clonal level (> 20% mutated allele fraction) in 10% of cases (76 out of 762) and at a subclonal level (mutated allele fraction 0.1%-20%) in 3.9% of patients (30 out of 762), with a strong correlation between the presence of ALKm and MNA (P < .001). Among 571 cases with known ALKa and ALKm status, a statistically significant difference in OS was observed between cases with ALKa or clonal ALKm versus subclonal ALKm or no ALK alterations (5-year OS: ALKa [n = 19], 26% [95% CI, 10 to 47], clonal ALKm [n = 65] 33% [95% CI, 21 to 44], subclonal ALKm (n = 22) 48% [95% CI, 26 to 67], and no alteration [n = 465], 51% [95% CI, 46 to 55], respectively; P = .001). Importantly, in a multivariate model, involvement of more than one metastatic compartment (hazard ratio [HR], 2.87; P < .001), ALKa (HR, 2.38; P = .004), and clonal ALKm (HR, 1.77; P = .001) were independent predictors of poor outcome. Conclusion: Genetic alterations of ALK (clonal mutations and amplifications) in HR-NB are independent predictors of poorer survival. These data provide a rationale for integration of ALK inhibitors in upfront treatment of HR-NB with ALK alterations. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-11 2021-06-11T00:00:00Z 2022-02-04T17:35:31Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.18/7937 |
url |
http://hdl.handle.net/10400.18/7937 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11. 0732-183X 10.1200/JCO.21.00086 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
American Society of Clinical Oncology |
publisher.none.fl_str_mv |
American Society of Clinical Oncology |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132172375818240 |